Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ophtha.2016.04.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endoscopic mucosal resection and open-lid submucosal biopsy for the diagnosis of diffuse infiltrative gastric cancer: a retrospective observational study.
Scand J Gastroenterol
December 2024
Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Background And Study Aims: Diffuse infiltrative gastric cancer can be difficult to diagnose owing to a lack of endoscopic features in the superficial mucosa. Moreover, a forceps biopsy may not reveal a pathological diagnosis. We aimed to evaluate the diagnostic yield and safety of endoscopic mucosal resection (EMR) and 'open-lid submucosal biopsy', a technique wherein EMR followed by biopsy of the ulcer floor is performed for a pathological diagnosis.
View Article and Find Full Text PDFNecessity of splenectomy for antral-type scirrhous gastric cancer.
Eur J Surg Oncol
October 2024
Gastric Surgery Division, National Cancer Center Hospital, Tokyo, Japan.
Article Synopsis
- Total gastrectomy with splenic hilar nodal dissection is a common procedure for treating resectable scirrhous gastric cancer (GC), but the necessity of splenectomy specifically for antral-type GC is uncertain.
- A study at the National Cancer Center Hospital analyzed patients with type IV GC from 2000 to 2018, focusing on those who underwent total gastrectomy with splenectomy and achieved successful tumor resections.
- Results showed no metastasis to the splenic hilar nodes in patients with antral-type GC, suggesting that splenectomy may not be needed for this subtype, while it was common in body-type GC cases.
The peculiar clinical presentation and diagnostic results of a case of widely metastatic cholangiocellular carcinoma in a Siberian Husky dog.
Top Companion Anim Med
December 2024
Department of Comparative Pathobiology, Cummings School of Veterinary Medicine, Tufts University, 200 Westboro Road, North Grafton, MA 01536, USA. Electronic address:
Article Synopsis
- A six-year-old spayed female Siberian Husky presented with cervical pain, ataxia, respiratory changes, and significant weight loss, leading to a battery of diagnostic tests.
- Findings indicated serious health issues, including spinal myelopathy and signs suggestive of metastatic carcinoma, prompting humane euthanasia and further investigation through necropsy.
- The necropsy revealed multiple tumors consistent with cholangiocellular carcinoma, highlighting challenges in prior diagnostics and an unusual presentation with cervical pain likely linked to spinal metastasis.
Favorable outcome of immunotherapy in a rare subtype of hepatocellular carcinoma: a case report and literature review.
Front Oncol
April 2024
Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Scirrhous hepatocellular carcinoma (S-HCC) represents an uncommon subtype of HCC. During radiological evaluation this unique subtype is frequently mistaken as cholangiocarcinoma, fibrolamellar HCC, or metastatic adenocarcinoma. Here, we present the case of a 50-year-old woman with a large hepatic mass.
View Article and Find Full Text PDFRandomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer.
Future Oncol
October 2023
Division of Gastric Surgery, Shizuoka Cancer Center, Nagaizumi, 411-8777, Japan.
Macroscopic type 4 and large type 3 gastric cancer, mostly overlapping with scirrhous or type, exhibit a highly invasive nature and show unfavorable prognosis after curative surgery, even with adjuvant chemotherapy. A randomized phase III trial (JCOG0501) failed to demonstrate a survival advantage of neoadjuvant chemotherapy with S-1 plus cisplatin for this population. The current authors initiated a randomized phase II study comparing neoadjuvant chemotherapy with 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for type 4 and large type 3 gastric cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!